Kunshi Biotech completed tens of millions of yuan in angel round financing

Recently, Kunshi Biotechnology (Shenzhen) Co., Ltd. (referred to as “Kunshi Bio” or the company), a technology platform for gene editing, biomaterials and synthetic biology-driven engineered macrophages to treat solid tumors, announced the completion of tens of millions of RMB angel round financing. This round of investment was jointly invested by well-known venture capital institutions in the industry such as Australia Bank Capital and Riemann Conjecture. The funds obtained will be used for laboratory platform construction, pipeline research and development and preclinical experiments, patent layout and company operations.

Kunshi Bio was established in Shenzhen in April 2021. It is the first engineered macrophage technology platform in China driven by gene editing, biomaterials and synthetic biology, focusing on the development and clinical application of macrophage drugs for the treatment of solid tumors. company. It has pioneered the creation of the world’s first closed-loop industrial chain centered on macrophages. Its core platforms include the “24H-CAR” technology platform that can complete the preparation of chimeric antigen receptor macrophages (CAR-M) on the same day; the enhanced synthetic platform “ADM-CAR” based on iterative screening of macrophage activation domains; The “Del-M” macromolecule delivery platform using macrophages as the carrier and the “M-DB” subtype database and target database platform that can be the optimal source of CAR-M innovation for solid tumors in different tissues. Relying on these four platforms, the company has the core capability to build CAR-M-based clinical pipelines for solid tumors in batches.

The founder, Dr. Yin Xiushan, is a senior researcher at Karolinska Institutet in Sweden, with more than fifteen years of cell biology research and industry background. He has successively engaged in research and held positions in the Academy of Military Medical Sciences, the European Molecular Biology Laboratory (EMBL), the Medical School of the University of Cologne, the Max-Delbrück Center for Molecular Medicine and the Karolinska Institute in Sweden. He has presided over a total of 8 international and domestic funds, with a total funding of 40 million yuan. He has published more than 20 articles in Nature Cell Biology, Nature Communications Biology, Clinical chemistry, Cell Research, Heliyon, etc., more than 40 patents, and completed 4 product development and transformation. Successfully advanced 2 stem cell drugs into IIT trials. He has successively won the first prize of Beijing Science and Technology Award, the second prize of Chinese Medical Association, and the leading talents of Liaoning Province.